Noxopharm Ltd. (AU:NOX) has released an update.
Noxopharm Limited has announced the completion of its SOF-SKN™ lupus medication formulation, a vital milestone ahead of the HERACLES clinical trial. The newly finalized topical formula is designed to deliver the drug effectively to the dermis layer of the skin, showing sustained release over 48 hours. The company’s Sofra™ technology platform is gaining international interest, with multiple material transfer agreements already in place, signaling potential commercialization and collaboration.
For further insights into AU:NOX stock, check out TipRanks’ Stock Analysis page.